Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Université Paris Cité, F-75005, Paris, France.
INSERM, U900, 75005, Paris, France.
Nat Commun. 2024 Apr 5;15(1):2966. doi: 10.1038/s41467-024-47002-3.
Between 30% and 70% of patients with breast cancer have pre-existing chronic conditions, and more than half are on long-term non-cancer medication at the time of diagnosis. Preliminary epidemiological evidence suggests that some non-cancer medications may affect breast cancer risk, recurrence, and survival. In this nationwide cohort study, we assessed the association between medication use at breast cancer diagnosis and survival. We included 235,368 French women with newly diagnosed non-metastatic breast cancer. In analyzes of 288 medications, we identified eight medications positively associated with either overall survival or disease-free survival: rabeprazole, alverine, atenolol, simvastatin, rosuvastatin, estriol (vaginal or transmucosal), nomegestrol, and hypromellose; and eight medications negatively associated with overall survival or disease-free survival: ferrous fumarate, prednisolone, carbimazole, pristinamycin, oxazepam, alprazolam, hydroxyzine, and mianserin. Full results are available online from an interactive platform ( https://adrenaline.curie.fr ). This resource provides hypotheses for drugs that may naturally influence breast cancer evolution.
在患有乳腺癌的患者中，有 30%至 70%的患者存在先前存在的慢性疾病，超过一半的患者在诊断时正在长期服用非癌症药物。初步的流行病学证据表明，一些非癌症药物可能会影响乳腺癌的风险、复发和生存。在这项全国性队列研究中，我们评估了诊断时使用药物与生存之间的关系。我们纳入了 235368 名患有新诊断的非转移性乳腺癌的法国女性。在对 288 种药物的分析中，我们确定了八种与总生存或无病生存呈正相关的药物：雷贝拉唑、阿仑平滑肌、阿替洛尔、辛伐他汀、罗苏伐他汀、雌三醇（阴道或经粘膜）、孕二烯酮和羟丙甲纤维素；以及八种与总生存或无病生存呈负相关的药物：富马酸亚铁、泼尼松龙、卡比马唑、普瑞巴林、奥沙西泮、阿普唑仑、羟嗪和米氮平。完整的结果可在一个互动平台（https://adrenaline.curie.fr）上在线获取。该资源为可能自然影响乳腺癌进展的药物提供了假设。
